China China has expanded to be the second largest pharmaceutical market globally with USD 137 billion in total spending in 2018, but growth has slowed from a 19% CAGR in 2008–2013 to an 8% CAGR in 2013–2018 and is expected to continue to decline to 3-6% through 2023, as the below…
Italy Managing partner of the law firm Herbert Smith Freehills in Italy, Laura Orlando is one of Italy’s leading life sciences specialists, with a focus on IP and regulatory matters. Together with Sara Balice, one of the firm’s senior associates they examine the Court of Justice of the European Union’s (CJEU) ruling on…
Switzerland Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan has described as the most successful in the company’s history. 2018 was a good year for Roche. The Swiss-headquartered pharma giant saw seven percent overall…
France Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on to cover the operational specifics of the affiliate and shares her insights on the French pharma ecosystem. When I…
China Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein engineering and their mission to become a highly differentiated oncology biotech company, and Alphamab’s dual China-US development strategy in support…
Algeria Ipsen’s Guillaume Freneuil gives his take on the importance of the Algerian market to the global group. If we are investing right now in Algeria it is because we envisage further growth here to be able to serve patient needs 33 percent of Sales within Ipsen are now in…
IFPMA Across the month of January, we at PharmaBoardroom surveyed our executive readership on attitudes towards the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)’s new Code of Practice, effective January 1st, 2019. To download the Code click here and to read our exclusive interview with Melissa Barnes, the IFPMA’s ethics…
Algeria Click here to download the Healthcare & Life Sciences Review Algeria 2019 report. Algeria, Africa’s largest country by area, stands as a promising investment destination for the global life sciences industry, with a sizeable local market and a growing number of multinationals choosing to base their regional operations out…
France Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy to keep MS at the core of its business while developing next-generation treatments in areas like Alzheimer’s, and the important…
Turkey Imports and exports in Turkish pharma between 2010 and 2017. Pharmaceutical exports grew to a total of USD 898 million in 2017. These charts show both the volume and value of imported and locally-produced drugs in the Turkish pharma market between 2010 and 2017. TL 13.33 billion (USD 2.57…
UK In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has dropped a big announcement that not only indicates the country’s commitment to the problem but also the imminent threat that…
Turkey Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment. Throughout many of the healthcare systems in North America and Europe, there is an increasing emphasis on outpatient and preventative care. In terms of health economics, governments see a great benefit in…
See our Cookie Privacy Policy Here
